Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P100049/S040

LINX Reflux Management System

Torax Medical · Decision date Jan 16, 2026

FDA DECISIONP100049/S040

What did the FDA decide?

FDA records P100049/S040 as a supplement to PMA P100049, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jan 16, 2026.

FDA approval order statement

replacement of microscope and micrometer to perform inspections of incoming components
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Gastroenterology, Urology
Decision date
Jan 16, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P100049/S040
Regulatory pathway
PMA supplement
Applicant
Torax Medical
Product code
LEI
Decision code
OK30
Decision date
Jan 16, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: IMPLANT, ANTI-GASTROESOPHAGEAL REFLUX.

Applicant
Torax Medical
Product code
LEI
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P100049/S038 · Related supplement

    LINX Reflux Management System

  2. P100049/S040 received

    Application receipt date recorded by FDA.

  3. P100049/S041 · Related supplement

    LINX Reflux Management System

  4. P100049/S040 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P100049. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P100049

Product / regulatory recordCompanyPathwayDecision dateSource
Torax MedicalPMA supplementOct 8, 2025FDA
Torax MedicalPMA supplementJan 16, 2026FDA

Explore the linked device profile

Other records with product code LEI

Product / regulatory recordCompanyPathwayDecision dateSource
Implantica CE Reflux , Ltd.PMA approvalAug 20, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Torax Medical

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
4545 Creek Rd., Cincinnati, OH, 45242

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records